Response to Methadone Maintenance Treatment is Associated with the MYOCD and GRM6 Genes
Tóm tắt
Background: There is increasing interest in the pharmacogenetic basis for explaining differences between patients in treatment outcome among methadone-treated subjects. Most studies have focused on genetic polymorphisms related to methadone pharmacokinetics and, to a lesser extent, those genes implicated in the pharmacodynamics of methadone.
Objective: This study aimed to investigate the associations between response to methadone maintenance treatment (MMT) and polymorphisms in genes coding for the OPRM1 opioid receptor, the metabotropic glutamate receptors GRM6 and GRM8, the nuclear receptor NR4A2, the photolyase enzyme cryptochrome 1 (CRY1), and the transcription factor myocardin (MYOCD), which have previously been associated with the risk of opioid dependence disorder.
Methods: The study used an association, case-control design, conducted in the setting of an MMT program in a drug abuse outpatient center in Barcelona, Spain. We recruited 169 opioid-dependent patients (diagnosed according to the Diagnostic and Statistical Manual of Mental Disorders [4th Edition] criteria) receiving MMT. The inclusion criteria included Caucasian ethnicity, being enrolled in MMT for at least 6 months, and receiving a stable methadone dose for the previous 2 months. The exclusion criteria included language-related barriers, severe cognitive impairment, or any medical disorder that would interfere with the research assessments. Single nucleotide polymorphism (SNP) variants in several candidate genes and regions were genotyped: MYOCD (rs1714984), GRM8 (rs1034576), CRY1 (rs1861591), GRM6 (rs953741), OPRM1 (rs1074287), NR4A2 (rs1405735), and the intergenic variants rs965972 (1q31.2) and rs1867898 (2q21.2). MMT response status was assessed by the number of opioid-positive controls detected by random urinalysis in the previous 2 months. We used the chi-squared test and p-value for the allele frequencies of the eight SNPs in responders versus nonresponders, and multivariate logistic regression analyses to examine associations between genotypes in the responder and ronresponder groups under codominant, dominant, and recessive models of inheritance.
Results: A final sample of 116 opioid-dependent patients were included and classified as methadone responders (n = 83) and nonresponders (n = 33), according to illicit opioid use detection in random urinalysis. The responders and nonresponders showed similar demographic and clinical characteristics. All SNPs were in Hardy-Weinberg equilibrium. Subjects carrying the AA genotype at rs1861591 CRY1; Chr 12: 105941056 G>A) had a higher risk of being nonresponders (odds ratio [OR] = 2.99; 95% CI 1.14, 7.85; = 0.035), although this difference disappeared with multiple testing corrections. Patients carrying the A allele at rs1714984 MYOCD; Chr 17: 12558425 G>A) had an increased risk of being nonresponders only if they were also carriers of the AG genotype at rs953741 GRM6; Chr5: 178262451 A>G) [OR= 10.83; 95% CI 2.52, 46.66; p = 0.006].
Conclusions: A positive association was observed between response to methadone and two variants in the genes MYOCD and GRM6. A pharmacogenetic epistatic effect between SNPs in MYOCD and GRM6 appears to modulate inter-individual variations in MMT response.
Tài liệu tham khảo
Kreek MJ, Zhou Y, Butelman ER, et al. Opiate and cocaine addiction: from bench to clinic and back to the bench. Curr Opin Pharmacol 2009 Feb; 9(1): 74–80
Nielsen DA, Ji F, Yuferov V, et al. Genotype patterns that contribute to increased risk for or protection from developing heroin addiction. Mol Psychiatry 2008 Apr; 13(4): 417–28
Amato L, Davoli M, Perucci CA, et al. An overview of systematic reviews of the effectiveness of opiate maintenance therapies: available evidence to inform clinical practice and research. J Subst Abuse Treat 2005 Jun; 28(4): 321–9
Haile CN, Kosten TA, Kosten TR. Pharmacogenetic treatments for drug addiction: alcohol and opiates. Am J Drug Alcohol Abuse 2008; 34(4): 355–81
Li Y, Kantelip JP, Gerritsen-van Schieveen P, et al. Interindividual variability of methadone response: impact of genetic polymorphism. Mol Diagn Ther 2008; 12(2): 109–24
Crettol S, Deglon JJ, Besson J, et al. ABCB1 and cytochrome P450 genotypes and phenotypes: influence on methadone plasma levels and response to treatment. Clin Pharmacol Ther 2006 Dec; 80(6): 668–81
Levran O, O’Hara K, Peles E, et al.ABCB1 (MDR1) genetic variants are associated with methadone doses required for effective treatment of heroin dependence. Hum Mol Genet 2008 Jul 15; 17(14): 2219–27
Barratt DT, Coller JK, Somogyi AA. Association between the DRD2 A1 allele and response to methadone and buprenorphine maintenance treatments. Am J Med Genet B Neuropsychiatr Genet 2006 Jun 5; 141B(4): 323–31
Crettol S, Besson J, Croquette-Krokar M, et al. Association of dopamine and opioid receptor genetic polymorphisms with response to methadone maintenance treatment. Prog Neuropsychopharmacol Biol Psychiatry 2008 Oct 1; 32(7): 1722–7
de Cid R, Fonseca F, Gratacos M, et al. BDNF variability in opioid addicts and response to methadone treatment: preliminary findings. Genes Brain Behav 2008 Jul; 7(5): 515–22
Doehring A, Hentig N, Graff J, et al. Genetic variants altering dopamine D2 receptor expression or function modulate the risk of opiate addiction and the dosage requirements of methadone substitution. Pharmacogenet Genomics 2009 Jun; 19(6): 407–14
Torrens M, Serrano D, Astals M, et al. Diagnosing comorbid psychiatric disorders in substance abusers: validity of the Spanish versions of the Psychiatric Research Interview for Substance and Mental Disorders and the Structured Clinical Interview for DSM-IV. Am J Psychiatry 2004 Jul; 161(7): 1231–7
Gonzalez F, Salvador L, Martinez JM, et al. Estudio de fiabilidad y validez de la versión española de la entrevista clínica Addiction Severity Index (ASI). In: Iraurgi I, Gonzalez F, editors. Instrumentos de evaluación en drogode-pendencias. Madrid: Aula Medica Ediciones; 2002: 271–308
Gonzalez JR, Armengol L, Sole X, et al. SNPassoc: an R package to perform whole genome association studies. Bioinformatics 2007 Mar 1; 23(5): 644–5
Kalivas PW. The glutamate homeostasis hypothesis of addiction. Nat Rev Neurosci 2009 Aug; 10(8): 561–72
Lavreysen H, Dautzenberg FM. Therapeutic potential of group III metabotropic glutamate receptors. Curr Med Chem 2008; 15(7): 671–84
Hasin D, Liu X, Nunes E, et al. Effects of major depression on remission and relapse of substance dependence. Arch Gen Psychiatry 2002 Apr; 59(4): 375–80
Nestler EJ. Molecular basis of long-term plasticity underlying addiction. Nat Rev Neurosci 2001 Feb; 2(2): 119–28
Kelley AE. Memory and addiction: shared neural circuitry and molecular mechanisms. Neuron 2004 Sep 30; 44(1): 161–79
Pipes GC, Creemers EE, Olson EN. The myocardin family of transcriptional coactivators: versatile regulators of cell growth, migration, and myogenesis. Genes Dev 2006 Jun 15; 20(12): 1545–56
Chow N, Bell RD, Deane R, et al. Serum response factor and myocardin mediate arterial hypercontractility and cerebral blood flow dysregulation in Alzheimer’s phenotype. Proc Natl Acad Sci U S A 2007 Jan 16; 104(3): 823–8
Falcon E, McClung CA. A role for the circadian genes in drug addiction. Neuropharmacology 2009; 56Suppl. 1: 91–6
Kosobud AE, Gillman AG, Leffel 2nd JK, et al. Drugs of abuse can entrain circadian rhythms. Scientific World J 2007 Nov 2; 7: 203–12
Petrzilka S, Taraborrelli C, Cavadini G, et al. Clock gene modulation by TNF-alpha depends on calcium and p38 MAP kinase signaling. J Biol Rhythms 2009 Aug; 24(4): 283–94
Fernandez-Espejo E, Ramiro-Fuentes S, Rodriguez de Fonseca F. The absence of a functional peroxisome proliferator-activated receptor-alpha gene in mice enhances motor sensitizing effects of morphine, but not cocaine. Neuroscience 2009 Dec 1; 164(2): 667–75
Niwa M, Nitta A, Yamada K, et al. The roles of glial cell line-derived neurotrophic factor, tumor necrosis factor-alpha, and an inducer of these factors in drug dependence. J Pharmacol Sci 2007 Jun; 104(2): 116–21
Reynolds KK, Ramey-Hartung B, Jortani SA. The value of CYP2D6 and OPRM1 pharmacogenetic testing for opioid therapy. Clin Lab Med 2008 Dec; 28(4): 581–98
Wu WD, Wang Y, Fang YM, et al. Polymorphism of the micro-opioid receptor gene (OPRM1 118A>G affects fentanyl-induced analgesia during anesthesia and recovery. Mol Diagn Ther 2009; 13(5): 331–7
Farre M, Mas A, Torrens M, et al. Retention rate and illicit opioid use during methadone maintenance interventions: a meta-analysis. Drug Alcohol Depend 2002 Feb 1; 65(3): 283–90
Simpson DD. Treatment for drug abuse: follow-up outcomes and length of time spent. Arch Gen Psychiatry 1981 Aug; 38(8): 875–80